1. Home
  2. YMAB vs CPSS Comparison

YMAB vs CPSS Comparison

Compare YMAB & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YMAB
  • CPSS
  • Stock Information
  • Founded
  • YMAB 2015
  • CPSS 1991
  • Country
  • YMAB United States
  • CPSS United States
  • Employees
  • YMAB N/A
  • CPSS N/A
  • Industry
  • YMAB Biotechnology: Pharmaceutical Preparations
  • CPSS Finance: Consumer Services
  • Sector
  • YMAB Health Care
  • CPSS Finance
  • Exchange
  • YMAB Nasdaq
  • CPSS Nasdaq
  • Market Cap
  • YMAB 270.5M
  • CPSS 225.2M
  • IPO Year
  • YMAB 2018
  • CPSS 1992
  • Fundamental
  • Price
  • YMAB $5.72
  • CPSS $10.52
  • Analyst Decision
  • YMAB Strong Buy
  • CPSS
  • Analyst Count
  • YMAB 10
  • CPSS 0
  • Target Price
  • YMAB $21.10
  • CPSS N/A
  • AVG Volume (30 Days)
  • YMAB 542.6K
  • CPSS 29.4K
  • Earning Date
  • YMAB 03-04-2025
  • CPSS 03-14-2025
  • Dividend Yield
  • YMAB N/A
  • CPSS N/A
  • EPS Growth
  • YMAB N/A
  • CPSS N/A
  • EPS
  • YMAB N/A
  • CPSS 0.87
  • Revenue
  • YMAB $84,553,000.00
  • CPSS $184,246,000.00
  • Revenue This Year
  • YMAB $6.41
  • CPSS N/A
  • Revenue Next Year
  • YMAB $18.15
  • CPSS $17.21
  • P/E Ratio
  • YMAB N/A
  • CPSS $12.11
  • Revenue Growth
  • YMAB N/A
  • CPSS N/A
  • 52 Week Low
  • YMAB $5.60
  • CPSS $7.03
  • 52 Week High
  • YMAB $20.90
  • CPSS $12.73
  • Technical
  • Relative Strength Index (RSI)
  • YMAB 35.08
  • CPSS 38.44
  • Support Level
  • YMAB $5.60
  • CPSS $10.70
  • Resistance Level
  • YMAB $6.57
  • CPSS $11.67
  • Average True Range (ATR)
  • YMAB 0.38
  • CPSS 0.47
  • MACD
  • YMAB 0.10
  • CPSS -0.08
  • Stochastic Oscillator
  • YMAB 11.43
  • CPSS 0.00

About YMAB Y-mAbs Therapeutics Inc.

Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S.-based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent, by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: